AstraZeneca’s Imfinzi combination cuts death risk 42% in bladder cancer trial
AZN•AstraZeneca’s Imfinzi and enfortumab vedotin combination cut the risk of death by 42% in the Phase III VOLGA bladder cancer trial. The FDA granted the regimen priority review in September 2026.
1. VOLGA trial results
The combination improved survival versus standard care and reduced progression or recurrence in patients ineligible for cisplatin-based chemotherapy or who refused it. No new safety signals emerged, though severe adverse events were more common with the combination. Results are being presented at the ESMO Congress 2026 in Madrid and were simultaneously published in The New England Journal of Medicine.
